KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Debt Ratio (2016 - 2025)

Historic Debt Ratio for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 0.45.

  • Emergent BioSolutions' Debt Ratio rose 134.86% to 0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.45, marking a year-over-year increase of 134.86%. This contributed to the annual value of 0.48 for FY2024, which is 9501.3% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Debt Ratio stood at 0.45, which was up 134.86% from 0.47 recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Debt Ratio peaked at 0.48 during Q4 2024, and registered a low of 0.14 during Q4 2022.
  • Its 5-year average for Debt Ratio is 0.31, with a median of 0.29 in 2021.
  • Its Debt Ratio has fluctuated over the past 5 years, first plummeted by 4823.92% in 2022, then surged by 9501.3% in 2024.
  • Emergent BioSolutions' Debt Ratio (Quarter) stood at 0.27 in 2021, then tumbled by 48.24% to 0.14 in 2022, then skyrocketed by 72.89% to 0.24 in 2023, then surged by 95.01% to 0.48 in 2024, then dropped by 4.97% to 0.45 in 2025.
  • Its Debt Ratio was 0.45 in Q3 2025, compared to 0.47 in Q2 2025 and 0.47 in Q1 2025.